Akt, 14-3-3ζ, and vimentin mediate a drug-resistant invasive phenotype in diffuse large B-cell lymphoma

References

• Ng AK. Diffuse large B cell lymphoma. Semin Radiat Oncol 2007;17:169–75.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Rummel MJ. Recent advances in NHL. Clin Adv Hematol Oncol 2010;9:2–11.
   Google Scholar
• Woolley PV, Osborne CK, Levi JA, Wiernik PH, Canellos GP. Extranodal presentation of non-Hodgkin's lymphomas in the testis. Cancer 1976;38:1026–35.
   PubMed Web of Science ®Google Scholar
• Gabay C, Ben-Bassat H, Schlesinger M, Laskov R. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur J Immunol 1999;63:180–191.
   Web of Science ®Google Scholar
• Beckwith M, Longo DL, O'Connell CD, Moratz CM, Urba WJ. Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines. J Natl Cancer Inst 1990;82:501–509.
   PubMed Web of Science ®Google Scholar
• Mohammad RM, Mohamed AN, KuKuruga M, Smith MR, al-Katib A. A human B-cell lymphoma line with a de novo multidrug resistance phenotype. Cancer 1992;69:1468–1474.
   PubMed Web of Science ®Google Scholar
• Maxwell SA, Li Z, Jaya D, Ballard S, Ferrell J, Fu H. 14-3-3zeta mediates resistance of diffuse large B cell lymphoma to an anthracycline-based chemotherapeutic regimen. J Biol Chem 2009;284:22379–22389.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Blomgren, H, Hallstrom M. Possible role of acrolein in 4-hydroperoxycyclophosphamide-induced cell damage in vitro. Methods Find Exp Clin Pharmacol 1991;13:11–14.
   PubMed Web of Science ®Google Scholar
• Nociari MM, Shalev A, Benias P, Russo C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods 1998;213:157–167.
   PubMed Web of Science ®Google Scholar
• Ahmed SA, Gogal RM Jr, Walsh JE. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods 1994;170:211–224.
   PubMed Web of Science ®Google Scholar
• Su SC, Mendoza EA, Kwak HI, Bayless KJ. Molecular profile of endothelial invasion of three-dimensional collagen matrices: insights into angiogenic sprout induction in would healing. Am J Physiol Cell Physiol 2008;295:C1215–C1229.
   PubMed Web of Science ®Google Scholar
• Fisher KE, Pop A, Koh W, Anthis NJ, Saunders WB, Davis GE. Tumor cell invasion of collagen matrices requires coordinate lipid agonist-induced G-protein and membrane-type matrix metalloproteinase-1-dependent signaling. Mol Cancer 2006;5:69.
   PubMed Web of Science ®Google Scholar
• Bayless KJ, Kwak HI, Su SC. Investigating endothelial invasion and sprouting behavior in three-dimensional collagen matrices. Nat Protoc 2009;4:1888–1898.
   Web of Science ®Google Scholar
• Clarke L, Waxman DJ. Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 1989;49:2344–2350.
   PubMed Web of Science ®Google Scholar
• Murray GI, Taylor MC, McFadyen MC, et al. Tumour-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997;57:3026–3031.
   PubMed Web of Science ®Google Scholar
• Islam TC, Lindvall J, Wennborg A, Brandén LJ, Rabbani H, Smith CI. Expression profiling in transformed human B cells: influence of Btk mutations and comparison to B cell lymphomas using filter and oligonucleotide arrays. Eur J Immunol 2002;32:982–993.
   PubMed Web of Science ®Google Scholar
• Podolin PL, Prystowsky MB. The kinetics of vimentin RNA and protein expression in interleukin 2-stimulated T lymphocytes. J Biol Chem 1991;266:5870–5875.
   PubMed Web of Science ®Google Scholar
• Smith PG, Wang F, Wilkinson KN, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005;105:308–316.
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178–4186.
   PubMed Web of Science ®Google Scholar
• Faber AC, Dufort FJ, Blair D, Wagner D, Roberts MF, Chiles TC. Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem Pharmacol 2006;72:1246–1256.
   PubMed Web of Science ®Google Scholar
• Baohua Y, Xiaoyan Z, Tiecheng Z, Tao Q, Daren S. Mutations of the PIK3CA gene in diffuse large B cell lymphoma. Diagn Mol Pathol 2008;17:159–165.
   PubMed Web of Science ®Google Scholar
• Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 2009;114:2926–2935.
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Hansson U, Olsson M, et al. High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 2010;149:560–568.
   PubMed Web of Science ®Google Scholar
• Lertprasertsuke N, Tsutsumi Y, Maruyama T. B-cell lymphoma with vimentin-positive cytoplasmic inclusions. Acta Pathol Jpn 1991;41:473–479.
   PubMedGoogle Scholar
• Sarker AB, Akagi T, Yoshino T, Hoshida Y, Takahashi K, Horie Y. Expression of vimentin and epithelial membrane antigen in human malignant lymphomas. Acta Pathol Jpn 1990;40:581–587.
   PubMedGoogle Scholar
• Gustmann C, Altmannsberger M, Osborn M, Griesser H, Feller AC. Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin's lymphomas. Am J Pathol 1991;138:1413–1422.
   PubMed Web of Science ®Google Scholar
• Barnett SF, Defeo-Jones D, Fu S, et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem J 2005;385:399–408.
   PubMed Web of Science ®Google Scholar
• Eriksson JE, Dechat T, Grin B, et al. Introducing intermediate filaments: from discovery to disease. J Clin Invest 2009;119:1763–1771.
   PubMedGoogle Scholar
• Mendez MG, Kojima SI, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 2010;24:1838–1851.
   PubMed Web of Science ®Google Scholar
• Voulgari A, Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 2009;1796:75–90.
   PubMed Web of Science ®Google Scholar
• Bargagna-Mohan P, Hamza A, Kim YE, et al. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. Chem Biol 2007;14:623–634.
   PubMed Web of Science ®Google Scholar
• Tokunaga E, Oki E, Egashira A, et al. Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 2008;8:27–36.
   PubMed Web of Science ®Google Scholar
• Chatterjee D, Goldman M, Braastad CD, et al. Reduction of 9-nitrocamptothecin-triggered apoptosis in DU-145 human prostate cancer cells by ectopic expression of 14-3-3zeta. Int J Oncol 2004;25:503–509.
   PubMed Web of Science ®Google Scholar
• Neal CL, Yao J, Yang W, et al. 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009;69:3425–3432.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao J, Du Y, et al. Down-regulation of 14-3-3zeta suppresses anchorage-independent growth of lung cancer cells through anoikis activation. Proc Natl Acad Sci USA 2008;105:162–167.
   PubMed Web of Science ®Google Scholar
• Powell DW, Rane MJ, Chen Q, Singh S, McLeish KR. Identification of 14-3-3zeta as a protein kinase B/Akt substrate. J Biol Chem 2002;277:21639–21642.
   PubMed Web of Science ®Google Scholar
• Obsil T, Ghirlando R, Anderson DE, Hickman AB, Dyda F. Two 14-3-3 binding motifs are required for stable association of Forkhead transcription factor FOXO4 with 14-3-3 proteins and inhibition of DNA binding. Biochemistry 2003;42:15264–15272.
   PubMed Web of Science ®Google Scholar
• Yang H, Masters SC, Wang H, Fu H. The proapoptotic protein Bad binds the amphipathic groove of 14-3-3zeta. Biochim Biophys Acta 2001;1547:313–319.
   PubMed Web of Science ®Google Scholar
• Singh LP, Jiang Y, Cheng DW. Proteomic identification of 14-3-3zeta as an adapter for IGF-1 and Akt/GSK-3beta signaling and survival of renal mesangial cells. Int J Biol Sci 2006;3:27–39.
   PubMed Web of Science ®Google Scholar
• Zhou J, Shao Z, Kerkela R, et al. Serine 58 of 14-3-3zeta is a molecular switch regulating ASK1 and oxidant stress-induced cell death. Mol Cell Biol 2009;29:4167–4176.
   PubMed Web of Science ®Google Scholar
• DeFeo-Jones D, Barnett SF, Fu S, et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 2005;4:271–279.
   PubMed Web of Science ®Google Scholar
• Calleja V, Laguerre M, Parker PJ, Larijani B. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol 2009;7:e17.
   PubMed Web of Science ®Google Scholar
• Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 2005;18:13–24.
   PubMed Web of Science ®Google Scholar
• Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 2007;25:917–931.
   PubMed Web of Science ®Google Scholar
• Liao Y, Hung MC. Physiological regulation of Akt activity and stability. Am J Transl Res 2010;2:19–42.
   PubMed Web of Science ®Google Scholar
• Facchinetti V, Ouyang W, Wei H, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008;27:1932–1943.
   PubMed Web of Science ®Google Scholar
• Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005;24:7443–7454.
   PubMed Web of Science ®Google Scholar
• Fortier A-M, Themsche CV, Asselin E, Cadrin M. Akt isoforms regulate intermediate filament protein levels in epithelial carcinoma cells. FEBS Lett 2010;584:984–988.
   PubMed Web of Science ®Google Scholar
• Tavassoli M, Hardy C. Molecular basis of homing of intravenously transplanted stem cells to the marrow. Blood 1990;76:1059–1070.
   PubMed Web of Science ®Google Scholar
• Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301–314.
   PubMed Web of Science ®Google Scholar
• Nieminen M, Henttinen T, Merinen M, Marttila-Ichihara F, Eriksson JE, Jalkanen S. Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol 2006;8:156–162.
   PubMed Web of Science ®Google Scholar
• Rafa L, Dessein AF, Devisme L, et al. REG4 acts as a mitogenic, motility and pro-invasive factor for colon cancer cells. Int J Oncol 2010;36:689–698.
   PubMed Web of Science ®Google Scholar
• Park JK, Park SH, So K, Bae IH, Yoo YD, Um HD. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int J Oncol 2010;36:181–192.
   PubMed Web of Science ®Google Scholar
• Kim MR, Choi HK, Cho KB, Kim HS, Kang KW. Involvement of Pin1 induction in epithelial-mesenchymal transition of tamoxifen-resistant breast cancer cells. Cancer Sci 2009;100:1834–1841.
   PubMed Web of Science ®Google Scholar
• Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res 2007;67:1979–1987.
   PubMed Web of Science ®Google Scholar
• Kumar S, Bryant CS, Chamala S, et al. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer 2009;8:26.
   PubMed Web of Science ®Google Scholar
• Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005;23:2411–2422.
   PubMed Web of Science ®Google Scholar
• Jankowski K, Kucia M, Wysoczynski M, et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res 2003;63:7926–7935.
   PubMed Web of Science ®Google Scholar
• Hutcheson IR, Knowlden JM, Hiscox SE, et al. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res 2007;9:R50.
   Google Scholar
• Moro L, Arbini AA, Yao JL, di Sant'Agnese PA, Marra E, Greco M. Mitochondrial DNA depletion in prostate epithelial cells promotes anoikis resistance and invasion through activation of PI3K/Akt2. Cell Death Differ 2009;16:571–583.
   Google Scholar
• Li L, Wei XH, Pan YP, et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene 2010;29:5785–5795.
   PubMed Web of Science ®Google Scholar
• Zhu QS, Rosenblatt K, Huang KL, et al. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 2010 Sep 20. [Epub ahead of print].
   Web of Science ®Google Scholar
• Lahat G, Zhu QS, Huang KL, et al. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies. PLoS One 2010;5:e10105.
   PubMed Web of Science ®Google Scholar
• Zhang MH, Lee JS, Kim HJ, et al. HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis. Mol Cell Biochem 2006;281:111–121.
   PubMed Web of Science ®Google Scholar
• Yang X, Wang J, Liu C, et al. Cleavage of p53-vimentin complex enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of rheumatoid arthritis synovial fibroblasts. Am J Pathol 2005;167:705–719.
   PubMed Web of Science ®Google Scholar
• Yang C, Lu P, Lee FY, et al. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008;22:1755–1766.
   PubMed Web of Science ®Google Scholar
• Feuerhake F, Kutok JL, Monti S, et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005;106:1392–1399.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005;18:1377–1384.
   PubMed Web of Science ®Google Scholar
• Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003;101:4279–4284.
   PubMed Web of Science ®Google Scholar
• Amini RM, Berglund M, Rosenquist R, et al. A novel B-cell line (U-2932) established from a patient with diffuse large B-cell lymphoma following Hodgkin lymphoma. Leuk Lymphoma 2002;43:2179–2189.
   PubMed Web of Science ®Google Scholar
• Ohsawa M, Ikura Y, Fukushima H, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005;68:422–431.
   PubMed Web of Science ®Google Scholar
• Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010;115:3304–3313.
   PubMed Web of Science ®Google Scholar
• Al-Katib AM, Smith MR, Kamanda WS, et al. Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res 1998;4:1305–1314.
   PubMed Web of Science ®Google Scholar
• Tsukita S, Yonemura S. Cortical actin organization: lessons from ERM (ezrin/radixin/moesin) proteins. J Biol Chem 1999;274:34507–34510.
   PubMed Web of Science ®Google Scholar
• Ivetic A, Ridley AJ. Ezrin/radixin/moesin proteins and Rho GTPase signalling in leucocytes. Immunology 2004;112:165–176.
   PubMed Web of Science ®Google Scholar
• Verrills NM, Liem NL, Liaw TYE, Hood BD, Lock RB, Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia – an in vivo study. Proteomics 2006;6:1681–1694.
   PubMed Web of Science ®Google Scholar
• Maki M, Kitaura Y, Satoh H, Ohkouchi S, Shibata H. Structures, functions and molecular evolution of the penta-EF-hand Ca2+-binding proteins. Biochim Biophys Acta 2002;1600:51–60.
   PubMed Web of Science ®Google Scholar
• Yang YX, Chen ZC, Zhang GY, Yi H, Xiao ZQ. A subcelluar proteomic investigation into vincristine-resistant gastric cancer cell line. J Cell Biochem 2008;104:1010–1021.
   PubMed Web of Science ®Google Scholar
• Qi J, Liu N, Zhou Y, et al. Overexpression of sorcin in multidrug resistant human leukemia cells and its role in regulating cell apoptosis. Biochem Biophys Res Commun 2006;349:303–309.
   PubMed Web of Science ®Google Scholar
• Cornwell MM, Pastan I, Gottesman MM. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987;262:2166–2170.
   PubMed Web of Science ®Google Scholar
• Bruno NA, Slate DL. Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrug-resistant cells. J Natl Cancer Inst 1990;82:419–424.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu H, Han B, Zhang JT. Identification of 14-3-3sigma as a contributor to drug resistance in human breast cancer cells using functional proteomic analysis. Cancer Res 2006;66:3248–3255.
   Google Scholar
• Li Y, Chen HQ, Chen MF, et al. Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells. Life Sci 2009;84:882–887.
   PubMed Web of Science ®Google Scholar
• Selga E, Morales C, Noé V, Peinado MA, Ciudad CJ. Role of caveolin 1, E-cadherin, enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med Genomics 2008;1:35.
   PubMed Web of Science ®Google Scholar
• Johnsson A, Zeelenberg I, Min Y, et al. Identification of genes differentially expressed in association with acquired cisplatin resistance. Br J Cancer 2000;83:1047–1054.
   PubMed Web of Science ®Google Scholar